Serostim — Medica

Human Immunodeficiency Virus Infection with Wasting or Cachexia in an Adult

Initial criteria

age ≥ 18 years
Patient meets at least ONE of the following: documented unintentional weight loss of ≥ 10% from baseline OR weight < 90% of the lower limit of ideal body weight OR body mass index (BMI) ≤ 20 kg/m2
Patient has wasting or cachexia due to malabsorption, poor diet, opportunistic infection, or depression AND other causes have been addressed prior to starting somatropin
Patient has been on antiretroviral therapy or highly active antiretroviral therapy for ≥ 30 days prior to beginning Serostim and will continue antiretroviral therapy throughout Serostim treatment
Serostim is not being used solely for treatment of alterations in body fat distribution such as increased abdominal girth, lipodystrophy, excess abdominal fat, or dorsocervical fat pad
Patient has tried one appetite stimulant or other anabolic agent (e.g., megestrol acetate, dronabinol, oxandrolone) OR such agents are contraindicated

6 months